Alcidion Group Ltd (ASX: ALC) Share Price and News

Ms Wilson is a company director and Board advisor in Australia, UK and US and has more than 25 years of experience working within the healthcare, technology and life science sectors. She provides advice on complex stakeholder communication, issues management, investor and corporate relations, and business strategy to private and public companies, corporations, governments, and asset managers. She has mature governance and risk management experience.

Mr Smart is a global digital health leader at both an operational and non-executive level having recently stepped down as the Global Director of External Relations, Dedalus Group, a global digital health company. Based in the United Kingdom, Will is currently Digital Non-Executive Director, Great Western Hospitals NHS Foundation Trust and was previously the CIO for Health and Social Care for England. He has held executive roles in several NHS Trusts including as Group Chief Information Officer, Royal Free London NHS Foundation Trust. In his capacity as Digital Non-Executive Director, Great Western Hospitals NHS Foundation Trust, Will is a member of the Acute Hospitals Alliance EPR Joint Committee responsible for overseeing the implementation of a new EPR across Great Western, Royal University Hospital, and Salisbury Trusts. Will is also a Director of CareTech Partners Limited providing digital advisory and consultancy support to public and private organisations and a member of the Health and Social Care Council at TechUK, a member organisation that represents and supports the UK technology sector and works with government, regulators and stakeholders.

Ms Doyle has been CEO of Alcidion since 2018, prior to which she was CEO of MKM Health until it was acquired by Alcidion. She has been involved in large systems procurements and implementations of healthcare information technology across Australia, United Kingdom, New Zealand and Southeast Asia. Her background involves holding leading management roles at some of the largest healthcare software firms where she has had an impact on strategic product direction across
the health sector and believes astute application of information technology will support the transformation of healthcare delivery worldwide.

Mr Sharp has over 25 years senior executive experience in investment banking and corporate finance. From 2012-2020, Daniel was an Executive Director of Corporate Finance at Canaccord Genuity where he led dozens of equity capital market transactions and corporate finance advisory projects across the healthcare, life sciences, technologies, financial services and general industrials sectors. Prior to his executive role at Canaccord, Daniel headed the corporate finance division at two of Australia's independent Investment Banking/Stockbroking firms. He is closely connected to strong networks of institutional, family office and high net worth investors both in Australia and overseas. He is also a member of risk committee.

Prof Way brings a wealth of experience to the Board of Alcidion, having served as the Chief Executive of Alfred Health from 2009 to 2024 as well as having held several senior positions in the England National Health Service (NHS). Andrew also led the development of Monash Partners, Victorias first Academic Health Science Centre and was appointed as an Adjunct Clinical Professor in the School of Public Health and Preventative Medicine, Faculty of Medicine Nursing and Health Sciences, Monash University in 2015. In addition to his senior leadership roles, Professor Way holds several non-executive and advisory roles both in Australia and internationally including Chair of the Department of Healths HSV (Health Services Victoria) Board.

-

-

-